Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Castration Resistant Prostate Cancer
80%
Disease
61%
Malignant Neoplasm
61%
Overall Survival
53%
Progression Free Survival
45%
Androgen
43%
Neoplasm
41%
Phase II Trials
41%
Prostate Specific Antigen
38%
Docetaxel
35%
Chemotherapy
32%
Enzalutamide
25%
Renal Cell Carcinoma
24%
High Dose Chemotherapy
22%
Solid Malignant Neoplasm
20%
Pharmacokinetics
19%
Gemcitabine
19%
Biological Marker
18%
Abiraterone
17%
Clinical Trial
16%
Bone Metastasis
16%
Metastasis
15%
Atrasentan
14%
Transitional Cell Carcinoma
14%
Adverse Event
13%
Inflammatory Breast Cancer
13%
Prostate Carcinoma
13%
Kidney Metastasis
13%
Placebo
12%
Cisplatin
11%
Angiogenesis Inhibitor
11%
Preclinical Study
10%
Phase I Trials
10%
Cyclophosphamide
10%
Androgen Receptor
10%
Paclitaxel
9%
Carboplatin
9%
Maximum Tolerated Dose
9%
Orteronel
9%
Olaparib
9%
Fluorine 18
9%
Gefitinib
9%
Trastuzumab
9%
Abiraterone Acetate
9%
Celecoxib
9%
Etoposide
9%
Kidney Cancer
7%
Pharmacodynamics
7%
Vasculotropin
6%
Medicine and Dentistry
Prostate Cancer
66%
Malignant Neoplasm
46%
Diseases
35%
Castration Resistant Prostate Cancer
30%
Progression Free Survival
25%
Phase II Trials
23%
Arm
22%
Metastatic Carcinoma
19%
Neoplasm
18%
Overall Survival
17%
Prostate Specific Antigen
15%
Transitional Cell Carcinoma
14%
Urothelial Cancer
14%
High Dose Chemotherapy
13%
Positron Emission Tomography
13%
Stem Cell
13%
Radiation Therapy
13%
Cisplatin
13%
Angiostatin
13%
Plasminogen
13%
Angiogenesis Inhibitor
13%
Oncology
13%
Immunotherapy
11%
Quality of Life
11%
Clear Cell Renal Cell Carcinoma
11%
Androgen
11%
Emergency Medical Technician
10%
Prostatectomy
10%
Paclitaxel
9%
Prostate Carcinoma
9%
Fluorine-18
9%
Gemcitabine
9%
Olaparib
9%
Diagnostic Performance
9%
Inflammatory Breast Cancer
9%
Cancer
9%
Urothelium
9%
Clinical Trial
8%
Kidney Cancer
8%
Androgen Deprivation Therapy
8%
Enzalutamide
7%
Cancer Therapy
7%
Kidney Metastasis
7%
Androgen Receptor
7%
Adverse Event
7%
Cancer Recurrence
6%
Primary Tumor
6%
Systemic Therapy
6%
Abiraterone Acetate
6%
Vasculotropin
5%